Sacituzumab tirumotecan demonstrated activity in a phase 2 trial of patients with advanced TNBC who had received no prior treatment in the advanced setting.

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

Mitomycin plus BCG is as safe and effective as BCG alone, but the combination allows for a reduction in BCG doses and may help combat the BCG shortage.

Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...

Adjuvant cemiplimab improved DFS in patients with CSCC who had completed adjuvant radiotherapy and had a high risk of recurrence.

Zanubrutinib plus venetoclax elicited durable responses in patients with treatment-naïve CLL or SLL and high-risk genetic features.

The worse overall survival seen in transgender and gender-diverse patients may be due to treatment differences or non-breast cancer causes, researchers say.

Adding nivolumab to adjuvant CRT improved DFS in patients with locally advanced head and neck squamous cell carcinoma at high risk of relapse.

Adding tagitanlimab to treatment with gemcitabine and cisplatin improved PFS in patients with recurrent or metastatic nasopharyngeal cancer.

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

As of this writing, the role of PD-L1 inhibitors in prostate cancer remains limited to a subset of patients with metastatic microsatellite instability-high, mismatch repair-deficient, or tumor ...

The FDA has accepted for priority review the new drug application for sevabertinib (BAY 2927088) to treat certain patients with NSCLC.